NeuroGenomeX, Inc. Announces Agreement with Dr. Nathan Fountain, Professor of Neurology at the University of Virginia
August 2009, Madison, WI -- NeuroGenomeX, Inc. today completed an agreement with Dr. Nathan Fountain from the University of Virginia. Dr. Fountain and the University of Virginia will be the lead site for the clinical studies on NeuroGenomeX’s anti-epilepsy compound 2-deoxy-D-glucose (2DG).
"Adding Dr. Fountain to our development team tremendously strengthens our clinical program," said Bill Checovich, Ph.D., COO of NeuroGenomeX. "Nathan, having been involved in some 30 human epilepsy trials, is an expert at running clinical programs on new epilepsy treatment regimens, like our lead compound, 2DG."
Dr. Fountain is a world expert in the treatment of epilepsy and is Professor of Neurology at the University of Virginia. Since 1998 he has been Director of the F.E. Dreifuss Comprehensive Epilepsy Program at the University of Virginia School of Medicine. Dr. Fountain's interventional research interests include experimental therapeutics of unconventional drugs and devices for epilepsy. Other research interests include the natural history, outcome, and pathophysiology of nonconvulsive status epilepticus and studies of the natural history of changes in seizure frequency. He serves on the board of the National Association of Epilepsy Centers and the Epilepsy Foundation Professional Advisory Board.